543 related articles for article (PubMed ID: 18644188)
21. 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.
Vaidyanathan G; Larsen RH; Zalutsky MR
Cancer Res; 1996 Mar; 56(6):1204-9. PubMed ID: 8640798
[TBL] [Abstract][Full Text] [Related]
22. Sympathomimetic effects of MIBG: comparison with tyramine.
Graefe KH; Bossle F; Wölfel R; Burger A; Souladaki M; Bier D; Dutschka K; Farahati J; Bönisch H
J Nucl Med; 1999 Aug; 40(8):1342-51. PubMed ID: 10450687
[TBL] [Abstract][Full Text] [Related]
23. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
[TBL] [Abstract][Full Text] [Related]
24. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.
Sorensen A; Mairs RJ; Braidwood L; Joyce C; Conner J; Pimlott S; Brown M; Boyd M
J Nucl Med; 2012 Apr; 53(4):647-54. PubMed ID: 22414636
[TBL] [Abstract][Full Text] [Related]
25. Gene manipulation to enhance MIBG-targeted radionuclide therapy.
Mairs RJ; Fullerton NE; Cosimo E; Boyd M
Nucl Med Biol; 2005 Oct; 32(7):749-53. PubMed ID: 16243651
[TBL] [Abstract][Full Text] [Related]
26. Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas?
Kölby L; Bernhardt P; Johanson V; Wängberg B; Muth A; Jansson S; Forssell-Aronsson E; Nilsson O; Ahlman H
Ann N Y Acad Sci; 2006 Aug; 1073():491-7. PubMed ID: 17102116
[TBL] [Abstract][Full Text] [Related]
27. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
28. Bystander effect produced by radiolabeled tumor cells in vivo.
Xue LY; Butler NJ; Makrigiorgos GM; Adelstein SJ; Kassis AI
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13765-70. PubMed ID: 12368480
[TBL] [Abstract][Full Text] [Related]
29. Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labeled compounds in mouse testes: implications for radiopharmaceutical design.
Narra VR; Howell RW; Harapanhalli RS; Sastry KS; Rao DV
J Nucl Med; 1992 Dec; 33(12):2196-201. PubMed ID: 1460515
[TBL] [Abstract][Full Text] [Related]
30. Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy.
Alvarez D; Hogstrom KR; Brown TA; Ii KL; Dugas JP; Ham K; Varnes ME
Radiat Res; 2014 Dec; 182(6):607-17. PubMed ID: 25409122
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
[TBL] [Abstract][Full Text] [Related]
32. Imaging hNET reporter gene expression with 124I-MIBG.
Moroz MA; Serganova I; Zanzonico P; Ageyeva L; Beresten T; Dyomina E; Burnazi E; Finn RD; Doubrovin M; Blasberg RG
J Nucl Med; 2007 May; 48(5):827-36. PubMed ID: 17475971
[TBL] [Abstract][Full Text] [Related]
33. Effects of low and high LET radiations on bystander human lung fibroblast cell survival.
Baskar R; Balajee AS; Geard CR
Int J Radiat Biol; 2007 Aug; 83(8):551-9. PubMed ID: 17613128
[TBL] [Abstract][Full Text] [Related]
34. Efficient mutation induction by 125I and 131I decays in DNA of human cells.
Whaley JM; Little JB
Radiat Res; 1990 Jul; 123(1):68-74. PubMed ID: 2371380
[TBL] [Abstract][Full Text] [Related]
35. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.
Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN
Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120
[TBL] [Abstract][Full Text] [Related]
36. Dilution of irradiated cell conditioned medium and the bystander effect.
Ryan LA; Smith RW; Seymour CB; Mothersill CE
Radiat Res; 2008 Feb; 169(2):188-96. PubMed ID: 18220470
[TBL] [Abstract][Full Text] [Related]
37. Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles.
Gedda L; Fondell A; Lundqvist H; Park JW; Edwards K
J Nucl Med; 2012 Mar; 53(3):480-7. PubMed ID: 22323773
[TBL] [Abstract][Full Text] [Related]
38. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
39. Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.
Roa WH; Miller GG; McEwan AJ; McQuarrie SA; Tse J; Wu J; Wiebe LI
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):425-32. PubMed ID: 9607361
[TBL] [Abstract][Full Text] [Related]
40. Bystander responses induced by low LET radiation.
Prise KM; Folkard M; Michael BD
Oncogene; 2003 Oct; 22(45):7043-9. PubMed ID: 14557809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
